Prelude Therapeutics Inc (PRLD)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$189.4M
Stockholders' Equity
$133.7M
Cash & Equivalents
$26.3M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, Prelude Therapeutics Inc reported revenue of $5.7M, net income of -$13.9M, and total assets of $189.4M. Every figure below is taken directly from Prelude Therapeutics Inc's SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025$12.1M-$99.5M
FY2024$7.0M-$127.2M
FY2023—-$121.8M
FY2022—-$115.4M
FY2021—-$111.7M
FY2020—-$56.9M
FY2019—-$27.6M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KSep 10, 2026on EDGAR ↗
8-KAug 11, 2026on EDGAR ↗
10-QAug 11, 2026on EDGAR ↗
8-KJun 10, 2026on EDGAR ↗
10-QMay 12, 2026on EDGAR ↗
8-KMay 12, 2026on EDGAR ↗
DEF 14AApr 29, 2026on EDGAR ↗
8-KApr 21, 2026on EDGAR ↗
8-KApr 20, 2026on EDGAR ↗
8-KApr 15, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$189.4Msource ↗
Stockholders’ Equity$133.7Msource ↗
Cash & Equivalents$26.3Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue$5.7Msource ↗
Net Income-$13.9Msource ↗
Operating Income-$15.5Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$16.1Msource ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-0.14source ↗
EPS (basic)$-0.14source ↗
Shares Outstanding79.8Msource ↗
Cash from Operations-$15.6Msource ↗
Cash from Financing$85.8Msource ↗
Cash from Investing-$65.5Msource ↗

Insider activity

Form 4 open-market activity, last 180 days

No open-market Form 4 transactions filed in the last 180 days.

Restatement history

Point-in-time

No material restatements detected across 150 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.

Deeper fundamentals

A free API key reaches PRLD’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Get a free API key →See plans

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/PRLD

MCP tool: get_sec_fundamentals ticker=PRLD

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/PRLD/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=PRLD as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/PRLD/history

MCP tool: get_fundamentals_history ticker=PRLD

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/financial-health/PRLD

MCP tool: get_financial_health ticker=PRLD

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.